Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | 0.39 Increased by +125.16% | -1.18 Increased by +112.75% |
| Mar 30, 23 | -0.95 Increased by +25.20% | -1.53 Increased by +24.78% |
| Nov 10, 22 | -1.50 Decreased by -4.90% | -1.64 Increased by +5.21% |
| Aug 11, 22 | 5.58 Increased by +418.86% | -1.33 Increased by +390.64% |
| May 12, 22 | -1.55 Increased by +5.49% | -1.15 Decreased by -30.25% |
| Mar 24, 22 | -1.27 Increased by +33.85% | -1.29 Increased by +1.20% |
| Nov 12, 21 | -1.43 Increased by +31.90% | -1.47 Increased by +1.85% |
| Aug 12, 21 | -1.75 Increased by +16.67% | -2.00 Increased by +6.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by -100.00% | 11.41 M Increased by +214.55% | Increased by +N/A% Increased by +N/A% |
| Dec 31, 22 | -3.11 M Decreased by -22.55% | 30.35 M Increased by +583.93% | Decreased by -974.69% Decreased by -494.88% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -7.67 M Decreased by -9.60% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | 63.43 M Increased by +899.71% | Increased by +N/A% Increased by +N/A% |
| Mar 31, 22 | 3.11 M Increased by +28.62% | -9.96 M Decreased by -37.28% | Decreased by -319.88% Decreased by -6.73% |
| Dec 31, 21 | -2.54 M Decreased by -207.08% | -6.27 M Decreased by -88.83 K% | Increased by +246.83% Increased by +83.15 K% |
| Sep 30, 21 | 3.10 M Increased by +111.62% | -7.00 M Decreased by -3.03% | Decreased by -226.00% Increased by +51.31% |
| Jun 30, 21 | 3.11 M Increased by +557.51% | -7.93 M Decreased by -16.60% | Decreased by -255.05% Increased by +82.27% |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.